V.M. DELYAGIN, M.B. MELNIKOVA, G. SERIK

Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, 1 Samori Maschel Str., 117997 Moscow, Russian Federation

Delyagin V.M. — D. Med. Sc., Professor, Head of the Department of Functional Diagnostics, Head of the Department of Clinical Physiology, tel. (495) 287-65-70 (48-09), e-mail: delyagin-doktor@yandex.ru

Melnikova M.B. — Cand. Med. Sc., ophthalmologist, tel. (495) 287-65-70 (12-13), e-mail: Marina-del@yandex.ru

Serik G.I. — postgraduate student of the Department of Clinical Physiology, tel. (495) 287-65-70 (12-13), e-mail: serikgi@yandex.ru

The main factors are described which predispose to the development of dyslipidemia in patients with chronic diseases receiving long-term immunosuppressive therapy. The immunosuppressive therapy itself is an atherogenic factor. The results of research of vessels condition in type 1 diabetes in children are given. In particular, the change in the ratio of thickness of the intima and media is marked. Risk categories are listed, as well as concentrations of lipid fractions before specific therapy. Statins are possible prevention factor in patients older than 18, however in pediatric practice the polyunsaturated fatty acids are principally prescribed.

Key words: children, chronic diseases, dyslipidemia, cataract.

 

 

REFERENCES

1. Parham P. The immune system. NY: Garland Science, 2005. P. 344.

2. Goronzy J., Weyand C. The innate and adaptive immune systems. In: Goldman L., Ausiello D. Eds. Cecil Medicine. 23rd ed. Philadelphia, Saunders Elsevier, 2007. Pp. 569-788.

3. Poetker D., Reh D. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am., 2010, vol. 43, no. 4, pp. 753-776.

4. Krentz A., Dousset B., Mayer D., McMaster P., Buckels J., Cramb R., Smith J., Nattras M. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes, 1993, vol. 42, no. 12, pp. 1753-1759.

5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, vol. 106, no. 25, pp. 3143-3421.

6. Grundy S., Brewer J., Cleeman J., Smith S., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004, vol. 109, no. 3, pp. 433-438.

7. Grundy S., Hansen B., Smith J., Cleeman J., Kahn R. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation, 2004, vol. 109, no. 4, pp. 551-556.

8. Kahn R., Buse J., Ferrannini E. Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005, vol. 28, no. 9, pp. 2289-2304.

9. Grundy S., Cleeman J., Daniels S., Donato K., Eckel R., Franklin B., Gordon D., Krauss R., Savage P., Smith S., Spertus J., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, vol. 112, no. 17, pp. 2735-2752.

10. Majhail N., Flowers M., Ness K., Jagasia M., Carpenter P., Arora M., Johnston L., Martin P., Baker K., Lee S., Burns L. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2009, vol. 43, pp. 49-54.

11. Jun M., Foote C., Lv J., Neal B., Patel A., Nicholls S., Grobbee D., Cass A., Chalmers J., Perkvic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, 2010, vol. 375, no. 2729, pp. 1875-1884.

12. Michalik L., Auwerx J., Berger J., Chatterjee V., Glass C., Gonzalez F., Grimaldi P., Kadowaki T., Lazar M. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, vol. 58, no. 4, pp. 726-741.

13. Baron M., Leroyer A., Majd Z., Lalloyer F., Vallez E., Bantubungi K., Chinetti-Gbagnidi G., Delerive P., Boulanger C., Staels B., Tailleux A. PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis, 2011, vol. 218, no. 1, pp. 69-76.

14. Vodnala D., Rubenfire M., Brook R. Secondary causes of dyslipidemia. Am. J. Cardiol., 2012, vol. 110, no. 6, pp. 823-825.

15. Tichelli A., Bucher C., Rovo A., Stussi G., Stern M., Paulussen M., Halter J., Meyer-Monard S., Yeim D., Tsakiris D., Biedeman B., Passweg J., Gratwohn A. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood, 2007, vol. 110, no. 9, pp. 3463-3471.

16. Ritchie D., Seymour J., Roberts A., Szer J., Grigg A.P. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant, 2001, vol. 28, no. 1, pp. 101-103.

17. Benyunes M., Sullivan K., Deeg H., Meyer W., Fisher L., Basinger R., Jack M.K, Hicks J. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys, 1995, vol. 32, no. 3, pp. 661-670.

18. Tichelli A., Gratwohl A., Egger T., Roth J., Prünte A., Nissen C., Speck B. Cataract formation after bone marrow transplantation. Ann Intern Med., 1993, vol. 119, no. 12, pp. 1175-1180.

19. Toh T., Morton J., Coxon J., Elder M. Medical treatment of cataract. Clin Experiment Ophthalmol, 2007, vol. 35, no. 7, pp. 664-671.

20. Vasavada A., Vasavada V., Vasavada V., Praveen M., Johar K., Gajiar D., Arora A. Comparison of the effect of torsional and microburst longitudinal ultrasound on clear corneal incisions during phacoemulsification. J Cataract Refract Surg., 2012, vol. 38, no. 5, pp. 833-839.

21. Feldman G. The lipids in pathology of the eye. J Am Oil Chemist’s Society, 1967, vol. 44, issue 11, pp. 615-622.

22. Girao H., Mota C., Pereira P. Cholesterol may act as an antioxidant in lens membranes. Curr Eye Res., 1999, vol. 18, no. 6, pp. 448-454.

23. Siddique M., Tiwary B., Paul S. Phospholipid and protein contents of lens proteolipids in human senile cataract. Eye, 2010, vol. 24, no. 4, pp. 720-727.

24. Greiner J., Chylack L. Posterior subcapsular cataracts: histopathologic study of steroid-associated cataracts. Arch Ophthalmol., 2007, vol. 97, no. 1, pp. 135-144.

25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation, 2002, vol. 106, no. 25, pp. 3143-3421.

26. Smith S., Allen J., Blair S., Bonow R., Brass L., Fonarow G., Grunds S., Hiratzk L. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circualation, 2006, vol. 113, no. 19, pp. 2363-2372.

27. Peter H. Treating dyslipidemia in the high-risk patient. J Fam Med, 2010, vol. 59, no. 2, pp. E1-E9.

28. LaRosa J., Grundy S., Kastelein J., Kostis J., Graten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). For the Treating to New Targets (TNT) Steering Committee and Investigators. Am J Cardiol., 2007, vol. 100, no. 5, pp. 747-752.

29. Fodor J., Frolich J., Jacques J., McPherson P. Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Dyslipidemias. CMAJ, 2000, vol. 162, no. 10, pp. 1441-1447.

30. Couriel D., Carpenter P., Cutler C., Bolanos-Meade J., Treister N., Gea-Banacloche J., Shanghnessy P., Hymes S. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: Ancillary Therapy and Supportive Care Working Group Report. Biol. Blood Marrow Transplant., 2006, vol. 12, no. 4, pp. 375-396.

31. Golomb B., Evans M. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. Am J Cardiovasc Drugs, 2008, vol. 8, no. 6, pp. 373-418.

32. Mansi I., Frei C., Pugh M., Makris U., Mortensen E. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med., 2013, vol. 173, no. 14, pp. 1318-1326.

33. Golomb B., Evans M., Dimsdale J., White H. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med., 2012, vol. 172, no. 15, pp. 1180-1182.

34. Machan C., Hrynchak P., Irving E. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci., 2012, vol. 89, no. 8, pp. 1165-1171.

35. Carter A., Gomes T., Camacho X., Juurlinke D., Shah B., Mamdani M. Risk of incident diabetes among patients treated with statins: a population-based study. BMJ, 2013; DOI: 10.1136, bmj.f 2610

36. Goldberg R., Sabharwal A. Fish oil in the treatment of dyslipidemia. Curr Opin Endocrinol Diabetes Obes., 2008, vol. 15, no. 2, pp. 167-174.

37. Goldberg R. Omega 3 Fatty Acids in the Treatment of Dyslipidemia. The Lipid spin, 2007/2008, vol. 6, iss. 1, pp. 4-9.